Regeneron Pharmaceuticals
REGN
$4.39 (0.45%)
1D
1W
3M
1Y
5Y
ALL
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 3 days ago • REGN
2 Biotech Stocks to Buy in MayZacks Investment Research • 4 days ago • REGN
Regeneron (REGN) Announces Positive Data on Oncology CandidateBusiness Wire • 5 days ago • REGN
Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering FairThe Motley Fool • 5 days ago • REGN
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 YearsCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.